Strengthening Families & Communities LLC Trims Stake in Sanofi $SNY

Strengthening Families & Communities LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 9.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,000 shares of the company’s stock after selling 321 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Sanofi were worth $145,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock worth $62,000 after purchasing an additional 264 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock worth $338,000 after purchasing an additional 2,476 shares in the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Sanofi by 1.0% in the 1st quarter. Yousif Capital Management LLC now owns 60,191 shares of the company’s stock worth $3,338,000 after purchasing an additional 580 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Sanofi by 58.7% in the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after purchasing an additional 2,241 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Wednesday. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Trading Down 1.5%

SNY opened at $48.09 on Friday. The business has a 50 day simple moving average of $48.27 and a two-hundred day simple moving average of $49.82. The firm has a market capitalization of $118.09 billion, a price-to-earnings ratio of 11.56, a PEG ratio of 1.19 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a one year low of $44.62 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.73 EPS. Analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.